

## Section 5.

### Recommendation

The HTA Council **does NOT recommend the acceptance of the donation of meglumine acridone acetate** due to the following reasons:

1. It is not included in any CPG for COVID-19 and it is also not registered for the management of COVID-19 even in its country source, Russia. Its registered indication in Russia for the treatment of influenza and acute viral respiratory infections.
2. There were no reports of it being marketed in the global north (e.g., United States Singapore) where health systems are more robust.
3. There are no published completed and on-going clinical trials regarding its clinical efficacy and safety for COVID-19, to date. The three studies were indicated for influenza and while the outcomes of the studies are favourable, the overall low internal validity of the studies cannot support such claim.
4. There may be logistical and financial burden to dispose the donated medicine if there will be no users.

**For inquiries, you may contact the HTA Unit:**

4th Floor Pharmaceutical Division, Philippine Blood Disease and Transfusion Center, Diliman, Quezon City | Health Regulation Team, Department of Health, San Lazaro Compound, Sta. Cruz Manila | [hta.philippines@gmail.com](mailto:hta.philippines@gmail.com) | [doh.gov.ph](http://doh.gov.ph) | 8-875-7734 loc. 260 or 258